IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter

Sector
Healthcare
Filed
Jul 17, 2026
Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction.
Our two most advanced candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors designed to inhibit the transmission of pain. We are also advancing additional Nav1.8 candidates that can address alternative formulation and delivery approaches.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Historical financial performance
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1 | Jul 17, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | Jun 5, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | May 18, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Mar 27, 2026 | [Cover] Draft Registration Statement |
| D | Feb 13, 2025 | Notice of Exempt Offering of Securities |
Contact and headquarters details
Key executives and officers
Nima Farzan
Director, President and Chief Executive Officer
Neha Krishnamohan
Chief Financial Officer and Chief Business Officer
Neil Singla, M.D.
Chief Medical Officer
Timothy P. Walbert
Chair
Sara Bonstein
Director
Deborah Palestrant, Ph.D.
Director
Kevin Raidy
Director
Beth Seidenberg, M.D.
Director
Todd N. Smith
Director
James B. Tananbaum, M.D.
Director